FIGURE 5 from Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment
Year: 2023
Type: other
Abstract: Assess the impact of NF1 protein levels on treatment responses in PDX models. A, IHC was performed on indicated PDX models with varying degrees of NF1 levels. B, Palbociclib-bead pulldown was performed on the selected PDX tumors and NF1 was quantified by SureQuant. Data were normalized by TIC (see Materials and Methods) and shown as orange circles. Median NF1 levels in this cohort is marked by a solid line, while 75% and 25% quartile NF1 levels are marked by blue and red dotted lines, respectively. H-scores (which incorporate both staining intensity and proportion into a continuous semiquantitative score ranging 0–300) for NF1 IHC are shown as light gray bars. C, Tumors were first treated by fulvestrant after reaching a size of 200 mm3 before binimetinib was later added, as marked by a red arrow (+B). Treatment withdrawn from WHIM24 was marked by a green arrow. Tumor sizes are average ± SEM. N = 9 mice/arm.
Authors: Beom-Jun Kim, Ze-Yi Zheng, Jonathan T. Lei, Matthew V. Holt, Anran Chen, Jianheng Peng, Diana Fandino, Purba Singh, Hilda Kennedy, Yongchao Dou, María del Rosario Chica-Parrado, Emmanuel Bikorimana, Dan Ye, Yunguan Wang, Ariella B. Hanker, Nada Mohamed, Susan G. Hilsenbeck, Bora Lim, Jaya Ruth Asirvatham, Arun Sreekumar, Bing Zhang, George Miles, Meenakshi Anurag, Matthew J. Ellis, Eric C. Chang
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4385284806